Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 09:02 ET | Source: Research and Markets

Biopharmaceutical Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030: Growing Demand for Novel Treatments in Oncology, Autoimmune, and Genetic Disorders

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Biopharmaceutical Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
December 01, 2025 06:03 ET | Source: Research and Markets

$16.81 Bn Bispecific Antibodies Market Industry Trends and Global Forecasts, 2035 - Market Expanding Rapidly with 400+ Candidates in Development and 85+ Technology Platforms

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibodies Market Industry Trends and Global Forecasts to 2035: By Therapeutic Area, Mechanism of Action, Target Antigen, Antibody Format,...
November 27, 2025 09:02 ET | Source: Research and Markets

PD-L1 X 4-1BB (CD137) Bispecific Antibodies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
November 27, 2025 08:54 ET | Source: Research and Markets

Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors Competitive Intelligence Report 2025: Launch of the First Tocilizumab Biosimilar Antibodies Highlights the Attractiveness of the Market

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors" report has been added to ResearchAndMarkets.com's offering.This competitive...
November 26, 2025 07:15 ET | Source: Research and Markets

Monoclonal Antibody Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 670 Deals Signed Since 2019 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.This report contains a...
November 26, 2025 07:12 ET | Source: Research and Markets

Cancer Monoclonal Antibody Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 632 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a...
November 26, 2025 07:05 ET | Source: Research and Markets

Antibody Vaccine Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 1,486 Deals Signed Since 2019 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Antibody Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing...
November 14, 2025 07:21 ET | Source: Research and Markets

India Immunoglobin Market Boom Through 20252-2033: Set to Quadruple in Size with Tech Advancements Boosting Plasma-Derived Therapy Accessibility

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "India Immunoglobin Market Outlook 2025-2033" has been added to ResearchAndMarkets.com's offering.India's Immunoglobulin Market is expected to reach...
November 13, 2025 05:00 ET | Source: Numab Therapeutics AG

Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)

HORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology...
November 05, 2025 07:30 ET | Source: Compass Therapeutics

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC),...